Evidence map›Paper›PMID 39776163›Full record

ArticleMolecular cancer research : MCR2025

Exploring B7-H4's Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities.

Ning Kang, Hui Xue, Nelson K Y Wong, Yen-Yi Lin, Adam Classen, Rebecca Wu, Htoo Zarni Oo, Xin Dong, Angela Trinh, Dong Lin and 5 more

Abstract read
In one paragraph

Article in Molecular cancer research : MCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ning KangDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0000-0003-1881-6748
Hui XueDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0000-0002-8883-4717
Nelson K Y WongDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0000-0002-7003-6020
Yen-Yi LinVancouver Prostate Centre, Vancouver, Canada.ORCID 0000-0002-4379-1231
Adam ClassenDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0009-0003-4122-7260
Rebecca WuDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0009-0006-1032-6882
Htoo Zarni OoVancouver Prostate Centre, Vancouver, Canada.ORCID 0009-0009-8514-2713
Xin DongDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0000-0003-4736-8091
Angela TrinhGenomeMe Lab Inc., Richmond, Canada.ORCID 0009-0007-7018-4430
Dong LinDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0000-0002-0303-2599
Mads DaugaardVancouver Prostate Centre, Vancouver, Canada.ORCID 0000-0001-8383-055X
Christopher OngVancouver Prostate Centre, Vancouver, Canada.ORCID 0000-0002-0175-8724
Colin CollinsVancouver Prostate Centre, Vancouver, Canada.ORCID 0000-0001-6148-6110
Martin GleaveVancouver Prostate Centre, Vancouver, Canada.ORCID 0000-0003-4235-0167
Yuzhuo WangDepartment of Experimental Therapeutics, BC Cancer, Vancouver, Canada.ORCID 0000-0002-9749-8591

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
BC Cancer Foundation 1PRRG012Canadian Institutes of Health Research (CIHR) 153081Mitacs (Mitacs Canada) IT367734NCI NIH HHS P50 CA097186Pacific Northwest Foundation (PNF) P50 CA097186 Pilot projectTerry Fox Research Institute (TFRI) 1109
6 · The paper itself

Abstract

Prostate cancer is mainly managed with androgen deprivation therapy (ADT), but this often leads to a dormant state and subsequent relapse as lethal castration-resistant prostate cancer (CRPC). Using our unique prostate cancer patient-derived xenograft dormancy models, we investigated this critical dormant phase and discovered a selective increase in B7-H4 expression during the dormancy period following mouse host castration. This finding is supported by observations in clinical specimens of patients with prostate cancer treated with ADT. Differential expression analyses revealed the enrichment of extracellular matrix (ECM)-cell interaction pathways in B7-H4-positive cells. Functional assays demonstrated a crucial role of B7-H4 in maintaining dormancy within the ECM niche. Specifically, B7-H4 expression in LNCaP cells reduced proliferation within the dormant ECM in vitro and significantly delayed relapse in castrated hosts in vivo. These results shed light on the dynamic regulation of B7-H4 during prostate cancer dormancy and underscore its potential as a therapeutic target for preventing CRPC relapse. Implications: Our study identified membranous B7-H4 expression during ADT-induced dormancy, highlighting its potential as a therapeutic target for managing dormant prostate cancer and preventing fatal CRPC relapse.

Indexed as

Androgen AntagonistsExtracellular MatrixProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantV-Set Domain-Containing T-Cell Activation Inhibitor 1AnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiceXenograft Model Antitumor AssaysAndrogen AntagonistsV-Set Domain-Containing T-Cell Activation Inhibitor 1VTCN1 protein, human

Identifiers

PMID39776163
PMCPMC11972443

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.